Search

The Future of HIV Prevention with Dr. Jeanne Marrazzo

On January 20, join us and Jeanne Marrazzo, IDSA CEO and AVAC board member, for The Future of HIV Prevention: A People’s Research Agenda for Speed, Scale and Equity, a webinar exploring the PRA’s people-centered framework, what the PRA tracks, why it matters and what’s at stake.

Lenacapavir Regulatory Approval

Regulatory approvals, pending decisions, and appeals as of January 2026.

People’s Research Agenda 2025 Update Summary Table

The People’s Research Agenda sets out a people-centered framework for equitable and accelerated R&D and product introduction. It tracks the science, shows where investments align—or fail to align—with community-defined priorities, and spotlights critical gaps in the pipeline of prevention options needed to meet the diverse realities of all populations.

Cabotegravir Regulatory Approval

Regulatory approvals and those pending for cabotegravir as of January 2026.

HIV Vaccine Clinical Trials Pipeline

This graphic summarizes the state of HIV vaccine research, detailing the different immunological approaches in clinical trials, the specific candidates being studied, and the collaborative networks of funders and developers working toward an effective vaccine.

Global Health Watch: Assault on US vaccine policy, contradictions in HPV and HIV vaccine science; 14 countries sign America First MOUs

The assault on vaccine policy and confidence intensified this week as the US overhauled its childhood immunization schedule. Beyond the US, 14 countries have now signed bilateral health agreements with the US under the America First Global Health Strategy. At the same time, the US President signed a new executive order withdrawing the US from and defunding over 60 international organizations and treaties. And Germany reportedly plans to cut its funding by half for the World Health Organization’s Hub for Pandemic and Epidemic Intelligence.

24 Hours to Save AIDS Research

Six Resolutions and Resources for Advocates in 2026 

As we look to the year ahead, we start by taking stock of the profound disruptions of 2025 and how the field responded. With immense challenges and historic opportunities ahead, we are making resolutions for the new year and sharing resources to advance our collective work in the months to come.

EXPrESSIVE Phase 3 Trials Countries of MK-8527

Seventeen countries are hosting sites for the Phase 3 efficacy trials of a monthly PrEP pill, MK-8527, being developed by Merck (also known as MSD outside of the US and Canada). Merck announced the launch of the Phase 3 trials at IAS 2025 in Kigali. MK-8527 was found to be safe and well-tolerated in Phase 2 clinical trials.

Global Health Watch: A Year That Reshaped Global Health

The Lancet journal ended the year with a provocative editorial – 2025: an annus horribilis for health in the USA. But sadly, it was not just in the US; it has been a year of chaos and disruption globally. This 49th issue of Global Health Watch looks back—like many news stories this week—across 2025 to highlight the most consequential decisions, disruptions, and debates that defined the year and will continue to shape what comes next.